Haleon plc (HLN) Fair Value & Analysis
Healthcare · US · Market cap $39.6B · ISIN US4055521003
What is Haleon plc really worth?
Haleon plc
HLN · US
A solid business, but trading 29% above our fair value of $7.64.
Strengths
Risks
For context
Fair value as of: Aug 30, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Aug 30, 2026, revised from $7.62 to $7.64 (+0.3%) since Aug 13, 2026. Share price +0.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- A fairly wide model range ($4.86 to $12.41) leaves room in how you read the outcome.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.
How to read this chart
50‑month range $5.30 – $11.19 · fair‑value band $4.86 – $12.41 · the $9.86 price screens above the $7.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 30, 2026.
Analysis
Haleon plc (HLN) currently trades at $9.86, while our model-based Fair Value estimate is $7.64, implying the stock looks roughly 29.1% overvalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of $6.28 per share, and 0 of the 24 models we run sit above the $9.86 price. Bear case: the Dividend Discount group reads lowest at $1.52, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Haleon plc generated revenue of $11.0B at a net margin of 15.1%. Revenue grew 0.6% year over year. It earns a return on equity of 10.3%. Net debt stands at $7.3B. Fundamentals as of Aug 30, 2026
Our scenario range runs from $4.86 (bear case) to $12.41 (bull case); at $9.86, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 15% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −49% fair-value upside, at −23%, HLN screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $0.2903 per share, which is 3.8 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: Multiples ($6.28) versus Dividend Discount ($1.52). Highest evidence: FCF DCF (79).
Notify me when HLN reaches fair value
Put HLN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 58
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Full company description
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Haleon plc reported revenue of £11.0B in FY2025 versus £9.5B in FY2021, a compound +3.7%/yr. Reported net income was £1.6B in FY2025, compounding +4.1%/yr from FY2021.
HLN screens 29% overvalued. Compare with Merck KGaA →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- LCUT vs. HLN: Which Stock Is the Better Value Option?
- Jefferies raises Haleon price target to 410p on margin strength
- Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes
- Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 45/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
| Divi's Laboratories Limited DIVISLAB | ₹8,525 | ₹1,228 | −86% |
Compare Haleon plc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Haleon plc (HLN) overvalued or undervalued?
What is the fair value of HLN?
What is the quality score of HLN?
What is the revenue of Haleon plc (HLN)?
What is the net profit margin of HLN?
Does Haleon plc pay a dividend?
Watch Haleon plc in the live analysis
One click puts Haleon plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.